Correlation Engine 2.0
Clear Search sequence regions
Bookmark Forward

QuickView for Nizatidine (compound)


PubChem
Name: Nizatidine
PubChem Compound ID: 3033637
Description: A histamine H2 receptor antagonist with low toxicity that inhibits gastric acid secretion. The drug is used for the treatment of duodenal ulcers.
Molecular formula: C12H21N5O2S2
Molecular weight: 331.46 g/mol
Synonyms:
LY-139037; Gastrax; Acinon; Nizax; Acinon (TN); Cronizat; ZL-101; C07270; Distaxid; Naxidine.
show more »
DrugBank
Identification
Name: Nizatidine
Name (isomeric): DB00585
Drug Type: small molecule
Description: A histamine H2 receptor antagonist with low toxicity that inhibits gastric acid secretion. The drug is used for the treatment of duodenal ulcers.
Brand: Panaxid, Nizatidina [Spanish], Zinga, Ulcosol, Tazac, Nizatidinum [Latin], Nizaxid, Cronizat, Calmaxid, Zanizal, Splendil Er, Axid, Acinon, Antizid, Axid Ar, Naxidine, Distaxid, Ulxid, Nizax, Niatidine, Galitidin, Gastrax, Nizatidine [Usan:Ban:Inn:Jan]
Category: Anti-Ulcer Agents, Histamine H2 Antagonists
CAS number: 76963-41-2
Pharmacology
Indication: For the treatment of acid-reflux disorders (GERD), peptic ulcer disease, active benign gastric ulcer, and active duodenal ulcer.
Pharmacology:
Nizatidine is a competitive, reversible inhibitor of histamine at the histamine H2-receptors, particularly those in the gastric parietal cells. By inhibiting the action of histamine on stomach cells, nizatidine reduces stomach acid production. Nizatidine had no demonstrable antiandrogenic action. Full-dose therapy for the problems treated by nizati...
show more »
Mechanism of Action: Nizatidine competes with histamine for binding at the H2-receptors on the gastric basolateral membrane of parietal cells. Competitive inhibition results in reduction of basal and nocturnal gastric acid secretions. The drug also decreases the gastric acid response to stimuli such as food, caffeine, insulin, betazole, or pentagastrin.
Absorption: Rapid (bioavailability of nizatidine exceeds 70%)
Protein binding: 35%
Biotransformation: Hepatic. Less than 7% of an oral dose is metabolized as N2-monodes-methylnizatidine, an H2-receptor antagonist, which is the principal metabolite excreted in the urine. Other likely metabolites are the N2-oxide (less than 5% of the dose) and the S-oxide (less than 6% of the dose).
Half Life: 1-2 hours
Clearance: 40-60 L/h 7 – 14 L/h [functionally anephric patients]
Toxicity: Oral, rat LD50: 301 mg/kg. Symptoms of overdose include cholinergic-type effects including lacrimation, salivation, emesis, miosis, and diarrhea.
Affected organisms: Humans and other mammals
Interactions
Food interaction:
Avoid alcohol.
No iron, zinc or fluoride within 2 hours of taking this medication.
May take Vitamin D.
Take without regard to meals.
Avoid excessive quantities of coffee or tea (Caffeine).
show more »
Drug interaction:
ItraconazoleThe H2-receptor antagonist, nizatidine, may decrease the absorption of itraconazole.
AtazanavirThis gastric pH modifier decreases the levels/effects of atazanavir
EnoxacinNizatidine may decrease the absorption of enoxacin.
CefditorenH2-Antagonists such as nizatidine may decrease the serum concentration of cefditoren. Cefditoren prescribing information recommends to avoid concomitant use with H2-antagonists (eg, famotidine, ranitidine) and antacids as well. Consider alternative methods to minimize/control acid reflux (eg, diet modification) or alternative antimicrobial therapy if use of H2-antagonists can not be avoided.
KetoconazoleThe H2-receptor antagonist, nizatidine, may decrease the absorption of ketoconazole.

Targets


Transporters